Perceptive Advisors LLC's Voting Agreement for Astria Therapeutics Merger

Perceptive Advisors LLC and Perceptive Xontogeny entered into a Voting and Support Agreement with BioCryst Pharmaceuticals, Inc. on October 14, 2025. The agreement requires them to vote their shares of Astria Therapeutics, Inc. in favor of the merger with BioCryst and restricts the transfer of their shares until the merger is completed or the agreement is terminated. The merger agreement outlines the treatment of their Series X Convertible Preferred Stock and Warrants. The Voting Agreements will terminate upon the merger's completion, termination by BioCryst, or if the merger agreement is amended to reduce the consideration for Common Stock holders. This filing is an amendment to the Schedule 13D, reflecting these agreements.